Jinwu Financial News | Pharmaceutical stocks are generally improving. As of press release, Pharmaceuticals (02269) has risen 9.6%, Federal Pharmaceuticals (03933) and Rongchang Biotech (09995) have both risen by more than 7%, Cinda Biotech (01801) has risen 6.7%, and Kaituo Pharmaceutical (09939) has risen 5.44%.
According to the news, CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range. With the gradual stabilization of domestic policies and the fading of the innovation bubble, outstanding representatives of domestically produced innovative drugs and medical devices began to stand out under the storm. In the domestic hospital market and overseas market in 2024, it is expected that leading domestic companies will perform remarkably well.
According to the Huajin Securities Research Report, the pharmaceutical industry is currently in the bottoming stage. Whether from a valuation perspective or a rise or fall perspective, it is stable and improving on the fundamental demand side of the low-level industry, and the industry ecology is constantly being optimized.